Charles River Laboratories International, Inc. Stock
Stocks
CRL
US1598641074
Biotechnology & Medical Research
|
Market Closed -
NYSE
00:00:02 21/11/2026 +03
|
5-day change | 1st Jan Change | ||
| 314.32 USD | -4.15% |
|
-7.77% | +57.57% |
| Market Cap | 15.71B 14.33B 13.19B 12.01B 22.53B 1,456B 23.75B 161B 63.8B 794B 58.95B 57.71B 2,491B | P/E 2026 * |
37.3x | P/E 2027 * | 34.9x |
|---|---|---|---|---|---|
| Enterprise Value | 17.74B 16.18B 14.9B 13.56B 25.44B 1,644B 26.82B 181B 72.05B 896B 66.57B 65.17B 2,813B | EV / Sales 2026 * |
4.49x | EV / Sales 2027 * | 4.25x |
| Free-Float |
95.88% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| CRL | Delayed | |
| CRL | Real-time | ||
| RV6 | Real-time | ||
| CRL * | End-of-day quote | ||
| RV6 | Real-time | ||
| RV6 | Delayed | ||
| RV6 | Delayed | ||
| RV6 | Delayed | ||
| RV6 | End-of-day quote |
Last Transcript: Charles River Laboratories International, Inc.
| 1 day | -4.15% | ||
| 1 week | -7.77% | ||
| Current month | -12.55% | ||
| 1 month | +4.77% | ||
| 3 months | +8.39% | ||
| 6 months | +106.21% | ||
| Current year | +57.57% |
| 1 week | 310.52 | 343.57 | |
| 1 month | 310.52 | 379.63 | |
| Current year | 146.2 | 379.63 | |
| 1 year | 146.2 | 379.63 | |
| 3 years | 91.86 | 379.63 | |
| 5 years | 91.86 | 385.1 | |
| 10 years | 69.51 | 460.21 |
| Manager | Title | Age | Since |
|---|---|---|---|
Birgit Girshick
CEO | Chief Executive Officer | 56 | 05/05/2026 |
Glenn Coleman
DFI | Director of Finance/CFO | 58 | 06/04/2026 |
Namandje Bumpus
CTO | Chief Tech/Sci/R&D Officer | 45 | 12/01/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
James Foster
CHM | Chairman | 75 | 01/01/2000 |
Birgit Girshick
BRD | Director/Board Member | 56 | 05/05/2026 |
Martin MacKay
CHM | Chairman | 69 | 05/05/2026 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/22/26 A | Exercice | Director | 72,126 | 0.1511% | ||
| 10/21/26 A | Exercice | Executive/Senior Manager | 6,468 | 0.0135% | ||
| 10/5/26 A | Exercice | Executive/Senior Manager | 2,943 | 0.0062% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -4.15% | -7.77% | +94.46% | +66.27% | 15.71B | ||
| -2.49% | -6.35% | +51.07% | +64.95% | 65.42B | ||
| -0.63% | -3.81% | +6.95% | +88.55% | 58.91B | ||
| -2.37% | -2.22% | +22.96% | +83.44% | 55.24B | ||
| -2.19% | -6.02% | +10.50% | +109.19% | 45.66B | ||
| -1.89% | -9.33% | +13.03% | +20.04% | 41.29B | ||
| -0.93% | +1.67% | +20.83% | +45.03% | 36.82B | ||
| +1.11% | -8.59% | +128.56% | +655.74% | 34.48B | ||
| -0.80% | -1.73% | +75.29% | +56.47% | 32.5B | ||
| -2.17% | +19.70% | -30.57% | +469.42% | 31.69B | ||
| Average | -1.65% | -0.87% | +39.31% | +165.91% | 42B | |
| Weighted average by Cap. | -1.59% | -1.33% | +33.99% | +148.21% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.95B 3.6B 3.32B 3.02B 5.67B 366B 5.97B 40.41B 16.05B 200B 14.83B 14.52B 627B | 4.06B 3.7B 3.41B 3.1B 5.82B 376B 6.14B 41.5B 16.48B 205B 15.23B 14.91B 643B |
| Net income | 423M 386M 355M 323M 607M 39.21B 640M 4.33B 1.72B 21.37B 1.59B 1.55B 67.07B | 431M 393M 362M 329M 618M 39.92B 651M 4.4B 1.75B 21.76B 1.62B 1.58B 68.28B |
| Net Debt | 2.03B 1.85B 1.71B 1.55B 2.91B 188B 3.07B 20.76B 8.25B 103B 7.62B 7.46B 322B | 1.55B 1.41B 1.3B 1.18B 2.22B 143B 2.34B 15.82B 6.28B 78.15B 5.8B 5.68B 245B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/11/26 | $314.32 | -4.15% | 1,151,474 |
| 19/11/26 | $327.93 | -1.60% | 495,099 |
| 18/11/26 | $333.25 | +0.33% | 516,509 |
| 17/11/26 | $332.16 | -1.00% | 697,548 |
| 16/11/26 | $335.52 | -0.72% | 693,841 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- CRL Stock
Select your edition
All financial news and data tailored to specific country editions
















